TAKE Ltd Reports Q1 FY27 Profit of ₹1.06 Cr, Revenue ₹30.37 Cr
TAKE Limited announced its unaudited financial results for Q1 FY27, reporting a consolidated revenue of ₹30.37 Crore and a consolidated net profit of ₹1.06 Crore. This marks a significant turnaround from a net loss of ₹91.00 Lakhs in the corresponding prior-year period. The company also saw a dramatic increase in consolidated revenue from operations to ₹3,037.33 Lakhs and a substantial reduction in finance costs by 99.62% YoY. TAKE Limited is strategically entering the Longevity, Biohacking, and Preventive Healthcare market, leveraging its expertise in life sciences and clinical research. The company aims to capitalize on the growing global and Indian longevity markets with a dual business model combining science-backed nutraceuticals and digital health tools.
Key Highlights
- Consolidated Revenue from Operations reached ₹30.37 Crore in Q1 FY27.
- Consolidated Net Profit turned positive at ₹1.06 Crore, reversing prior year's loss.
- Finance costs decreased by 99.62% YoY to ₹0.07 Lakhs.
- EPS turned positive at ₹0.07 per share.
- Strategic entry into Longevity and Anti-Ageing market announced.
Price Impact
More from TAKE